赛升药业(300485.SZ)：2025年中报净利润为4778.62万元，同比扭亏为盈

Financial Performance - The company's total revenue is 197 million yuan, with a net profit attributable to shareholders of 47.7862 million yuan, an increase of 153 million yuan compared to the same period last year [1] - The net cash inflow from operating activities is 29.3419 million yuan [1] Key Financial Ratios - The latest debt-to-asset ratio is 4.65% [3] - The latest gross profit margin is 64.78%, an increase of 2.56 percentage points from the previous quarter [3] - The latest return on equity (ROE) is 1.40%, up 4.57 percentage points from the same period last year [3] - The diluted earnings per share (EPS) is 0.10 yuan, an increase of 0.32 yuan compared to the same period last year [3] - The latest total asset turnover ratio is 0.06 times [3] - The latest inventory turnover ratio is 0.84 times, an increase of 0.12 times, representing a year-on-year increase of 16.05% [3] Shareholder Information - The number of shareholders is 39,000, with the top ten shareholders holding 289 million shares, accounting for 60.07% of the total share capital [3] - The largest shareholder is "司設" with a holding ratio of 49.51% [3] - Other notable shareholders include "马丽" at 6.20% and "刘淑芹" at 1.82% [3]